# Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers

> **NCT02829372** · PHASE1 · TERMINATED · sponsor: **Ichnos Sciences SA** · enrollment: 36 (actual)

## Conditions studied

- HER2 Expressing Solid Tumours

## Interventions

- **DRUG:** CD3/HER2 bispecific monoclonal antibody

## Key facts

- **NCT ID:** NCT02829372
- **Lead sponsor:** Ichnos Sciences SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- **Last updated:** 2020-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02829372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02829372, "Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02829372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*